Viatris Inc. - Common Stock · Transaction Nov 18, 2025 · Filed Dec 15, 2025 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · VTRS
+1.10% · +$0.1900 · Vol Not reported
After hours · updated 16:00:00 ET
Viatris Inc
Pharmaceuticals
$17.44
Follow $VTRS
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $VTRS by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredWed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET · VTRS
MethodologyVTRS
Viatris Inc
Wed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
71/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Confidence: HIGH · 6 of 6 factors measured · Wed Oct 14 · session closed · Markets closed · resumes Thu 9:30 ET
AI Analysis
SovereignWhy is VTRS moving today?
Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Viatris Inc
PHARMACEUTICAL PREPARATIONSListed since
1973
Employees
30K
Country
US
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$17.27
Day high
$17.82
Day low
$17.24
Previous close
$17.25
52W high
$18.27
-4.54% from high
52W low
$9.93
90% of range
Market cap
$19.8B
EPS
$-0.3571
Beta
0.17
Shares out
1.1B
Avg volume
8.7M
VWAP
$17.25
Last session
Price history computed in-house
1W
-0.29%
1M
+4.68%
3M
+0.63%
1Y
+75.63%
YTD
+40.08%
SMA 50 $16.92 · above
SMA 200 $15.51 · above
52W position 90%
VTRS overview
Related filings and maps
Public disclosures
Congress activity in VTRS
11 filers · 6 buys · 13 sells (0 labeled S (partial)) · 2 other · Nov 17, 2020 to Nov 18, 2025 · House 19 / Senate 2
All available history · Latest 5 of 21 lines · Read Oct 14, 2026, 10:55 PM UTC
Official filing ↗
Viatris Inc. - Common Stock · Transaction Apr 8, 2025 · Filed May 8, 2025 · $1,001 to $15,000
Viatris Inc. - Common Stock · Transaction Mar 31, 2025 · Filed Apr 7, 2025 · $1,001 to $15,000
Viatris Inc. · Transaction Apr 10, 2023 · Filed May 19, 2023 · $1,001 to $15,000
Viatris Inc. · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
Federal contracts
VTRS contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for VTRS in this window.
Lobbying spend
VTRS lobbying filings, year to date.
Registered lobbying filings matched to Viatris Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for VTRS in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for VTRS.